跳转至内容
Merck
CN

261149

ingot, 99.9% trace rare earth metals basis

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
Lu
化学文摘社编号:
分子量:
174.97
UNSPSC Code:
12352300
PubChem Substance ID:
EC Number:
231-103-0
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

OHSVLFRHMCKCQY-UHFFFAOYSA-N

InChI

1S/Lu

SMILES string

[Lu]

assay

99.9% trace rare earth metals basis

form

ingot

reaction suitability

reagent type: catalyst
core: lutetium

resistivity

54 μΩ-cm, 20°C

bp

3402 °C (lit.)

mp

1663 °C (lit.)

density

9.84 g/mL at 25 °C (lit.)

Quality Level

pictograms

Flame

signalword

Danger

hcodes

pcodes

Hazard Classifications

Flam. Sol. 1

存储类别

4.1B - Flammable solid hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

S Shcherbinin et al.
Physics in medicine and biology, 57(18), 5733-5747 (2012-09-06)
We investigated the quantitative accuracy of SPECT/CT imaging studies as would be performed before and after targeted radionuclide therapy (TRT) using phantom experiments with (i) (99m)Tc, (ii) ¹⁷⁷Lu and (iii) ⁹⁰Y/¹⁷⁷Lu. While the experiment with (99m)Tc imitated a diagnostic scan
Jostein Dahle et al.
Anticancer research, 33(1), 85-95 (2012-12-26)
The monoclonal antibody against CD20, rituximab, alone, or as part of combination therapies, is standard therapy for non-Hodgkin's B-cell lymphoma. Despite significantly better clinical results obtained for beta-emitting radioimmunoconjugates (RICs), RICs targeting CD20 are not commonly used in medical practice
Ksenija R Kumrić et al.
Journal of separation science, 35(18), 2390-2398 (2012-09-22)
In this study, the mass transport resistance in liquid-phase microextraction (LPME) in a single hollow fiber was investigated. A mathematical model has been developed for the determination of the overall mass transfer coefficient based on the acceptor phase in an
Rebecca A Dumont et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(5), 762-769 (2013-03-16)
The gastrin-releasing peptide receptor (GRPr) is overexpressed in prostate cancer and is an attractive target for radionuclide therapy. In addition, inhibition of the protein kinase mammalian target of rapamycin (mTOR) has been shown to sensitize various cancer cells to the
S M van den Bosch et al.
Nuclear medicine and biology, 40(3), 415-423 (2013-02-06)
We report on our evaluation of the strain-promoted cyclooctyne-azide cycloaddition reaction for use in tumor pretargeting, comprising a side-by-side comparison of probes 1-3 bearing three distinct cyclooctyne moieties based respectively on the 1st and 2nd generation difluorinated cyclooctyne and the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持